FOLH1 and prostate carcinoma: Overall, the commercial availability of 2 approved kits for production of [68Ga]Ga-PSMA-11 PET has facilitated ready access to this important new prostate cancer imaging agent, and underpinned successful introduction of Pluvicto radiotherapy.